Rigel Pharmaceuticals (RIGL) Current Deferred Revenue (2011 - 2025)
Rigel Pharmaceuticals (RIGL) posted quarterly Current Deferred Revenue of $1.4 million for Q3 2025, little changed year-over-year from $1.4 million in Q3 2024, and little changed quarter-over-quarter from $1.4 million in Q2 2025.
Rigel Pharmaceuticals (RIGL) Current Deferred Revenue (2011 - 2025) Analysis & Trends
Rigel Pharmaceuticals' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $1.4 million for Q3 2025.
- In Q3 2025, Current Deferred Revenue changed 0.0% year-over-year to $1.4 million; the TTM figure through Sep 2025 stood at $1.4 million (changed 0.0% YoY), while the FY2024 annual figure was $1.4 million, changed 0.0% from the prior year.
- Current Deferred Revenue for Q3 2025 stood at $1.4 million, roughly flat from $1.4 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $9.5 million in Q1 2021, with the low at $1.4 million in Q2 2023.
- The 5-year median for Current Deferred Revenue is $1.4 million (2023), against an average of $2.2 million.
- The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue jumped 362.74% in 2021, then plunged 77.93% in 2022.
- Rigel Pharmaceuticals' Current Deferred Revenue stood at $2.6 million in 2021, then plunged by 47.27% to $1.4 million in 2022, then retreated by 1.02% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
- Business Quant data shows RIGL's Current Deferred Revenue at $1.4 million in Q3 2025, $1.4 million in Q2 2025, and $1.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 1.37 Mn |
| Jun 30, 2022 | 1.54 Mn |
| Mar 31, 2022 | 2.10 Mn |
| Dec 31, 2021 | 2.60 Mn |
| Sep 30, 2021 | 3.16 Mn |
| Jun 30, 2021 | 5.81 Mn |
| Mar 31, 2021 | 9.50 Mn |
| Dec 31, 2020 | 3.02 Mn |